Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis
Background. Two preparations of botulinum A toxin (BTX-A) are commercially available for the treatment of palmar hyperhidrosis (PPH): Botox (Allergan; 100 U/vial) and Dysport (Ipsen Limited; 500 U/vial), which are not bioequivalent. Results regarding an appropriate conversion factor between them ar...
Main Authors: | Hanan Mohamed El Kahky, Heba Mahmoud Diab, Dalia Gamal Aly, Nehal Magdi Farag |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | Dermatology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2013/686329 |
Similar Items
-
ONABOTULINUM TOXIN-A FOR OVERACTIVE BLADDER
by: Mahmood Shakir Abdulkarim
Published: (2016-12-01) -
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
by: Francesco Scaglione
Published: (2016-03-01) -
Abobotulinum Toxin A in the Treatment of Chronic Low Back Pain
by: Duarte Machado, et al.
Published: (2016-12-01) -
The effect of abobotulinum toxin A in the prophylactic treatment of refractory migraine
by: Afrouz Alipour, et al.
Published: (2016-12-01) -
Adverse Events of Intravesical Onabotulinum Toxin A Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
by: Yuh-Chen Kuo, et al.
Published: (2016-03-01)